Skip to main content

Table 3 Patient and tumour characteristics by Consensus Molecular Subtype

From: Molecular subtyping improves prognostication of Stage 2 colorectal cancer

 CMS1 (n = 60)CMS2 (n = 145)CMS3 (n = 38)CMS4 (n = 17)P-value*
 (n)%%%%
Age
 < 60y483.318.615.811.80.0188
 61-80y17048.353.860.552.9 
 > 80y9048.327.623.735.3 
Gender
 F16373.842.863.252.90.0009
 M14526.257.236.847.1 
Site
 Colon25398.375.984.264.7<  0.0001
 Rectum551.724.115.835.3 
Side
 Left17220715076.5<  0.0001
 Right13680295023.5 
Stagea
 15316.717.228.911.80.01449
 21285544.826.323.5 
 310526.729.742.147.1 
 4221.78.32.617.6 
  1. Patient and tumour characteristics by Consensus Molecular Subtype (CMS) given as percentages. N, total number of patients per group; P-value* is derived from analysis of classified tumours only and a P-value of < 0.05 is considered significant; y years, F Female, M Male; a Post-operative Tumour-Node-Metastasis staging